Abstract
Magnetic resonance imaging (MRI) techniques, such as T2-weighted and gadolinium-enhanced T1-weighted sequences, have long been used to diagnose multiple sclerosis (MS). However, these methods are limited in their ability to depict underlying disease pathology. A PubMed literature search was conducted to identify the publications discussing MRI in MS from 2010 to 2013, using the medical subject heading terms: “multiple sclerosis” and “grey/gray matter”, “brain atrophy”, “grey/gray matter atrophy”, “normal appearing white matter,” and “cortical lesions.” Recent proceedings of conferences on MRI were also used to identify emerging techniques. MRI-derived metrics can assess the microstructural, metabolic, and functional changes that occur in newly formed lesions and allow further characterization of diffuse degeneration in different central nervous system compartments across MS phenotypes. Advanced imaging techniques aim to complement our understanding of MS disease pathophysiology, which may facilitate the identification of markers that could be used to predict the clinical outcomes of agents in development.
Similar content being viewed by others
References
Geurts JJ, Calabrese M, Fisher E, Rudick RA (2012) Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol 11:1082–1092
Moll NM, Rietsch AM, Thomas S, Ransohoff AJ, Lee JC, Fox R, Chang A, Ransohoff RM, Fisher E (2011) Multiple sclerosis normal-appearing white matter: pathology-imaging correlations. Ann Neurol 70:764–773
Filippi M, Agosta F, Rocca MA (2007) Regional assessment of brain atrophy: a novel approach to achieve a more complete picture of tissue damage associated with central nervous system disorders? Am J Neuroradiol 28:260–261
Khaleeli Z, Sastre-Garriga J, Ciccarelli O, Miller DH, Thompson AJ (2007) Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 78:1076–1082
Fisniku LK, Chard DT, Jackson JS, Anderson VM, Altmann DR, Miszkiel KA, Thompson AJ, Miller DH (2008) Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 64:247–254
Calabrese M, De Stefano N, Atzori M, Bernardi V, Mattisi I, Barachino L, Morra A, Rinaldi L, Romualdi C, Perini P, Battistin L, Gallo P (2007) Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol 64:1416–1422
Inglese M, Oesingmann N, Casaccia P, Fleysher L (2011) Progressive multiple sclerosis and gray matter pathology: an MRI perspective. Mt Sinai J Med 78:258–267
Filippi M, Agosta F, Spinelli EG, Rocca MA (2013) Imaging resting state brain function in multiple sclerosis. J Neurol 260:1709–1713
Iannucci G, Tortorella C, Rovaris M, Sormani MP, Comi G, Filippi M (2000) Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. Am J Neuroradiol 21:1034–1038
Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G (2001) Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”. Neurology 57:731–733
Sbardella E, Tona F, Petsas N, Pantano P (2013) DTI measurements in multiple sclerosis: evaluation of brain damage and clinical implications. Mult Scler Int 2013:671730
Gallo A, Rovaris M, Riva R, Ghezzi A, Benedetti B, Martinelli V, Falini A, Comi G, Filippi M (2005) Diffusion-tensor magnetic resonance imaging detects normal-appearing white matter damage unrelated to short-term disease activity in patients at the earliest clinical stage of multiple sclerosis. Arch Neurol 62:803–808
De Stefano N, Narayanan S, Francis GS, Arnaoutelis R, Tartaglia MC, Antel JP, Matthews PM, Arnold DL (2001) Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 58:65–70
Narayanan S, De Stefano N, Francis GS, Arnaoutelis R, Caramanos Z, Collins DL, Pelletier D, Arnason BGW, Antel JP, Arnold DL (2001) Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 248:979–986
Mellergard J, Tisell A, Dahlqvist LO, Blystad I, Landtblom AM, Blennow K, Olsson B, Dahle C, Ernerudh J, Lundberg P, Vrethem M (2012) Association between change in normal appearing white matter metabolites and intrathecal inflammation in natalizumab-treated multiple sclerosis. PLoS One 7:e44739
Paty DW, Li DK (2001) Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. 1993 [classical article]. Neurology 57:S10–S15
Khan O, Shen Y, Caon C, Bao F, Ching W, Reznar M, Buccheister A, Hu J, Latif Z, Tselis A, Lisak R (2005) Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 11:646–651
Khan O, Caon C, Zak I et al (2008) Randomized, prospective, rater-blinded, four-year, pilot study to compare the effect of daily versus every-other-day glatiramer acetate 20 mg subcutaneous injections in relapsing-remitting multiple sclerosis. Mult Scler 14:902
Rocca MA, Valsasina P, Damjanovic D, Horsfield MA, Mesaros S, Stosic-Opincal T, Drulovic J, Filippi M (2013) Voxel-wise mapping of cervical cord damage in multiple sclerosis patients with different clinical phenotypes. J Neurol Neurosurg Psychiatry 84:35–41
Losseff N, Kingsley D, McDonald W, Miller D, Thompson A (1996) Clinical and magnetic resonance imaging predictors of disability in primary and secondary progressive multiple sclerosis. Mult Scler 1:218–222
Horsfield MA, Sala S, Neema M, Absinta M, Bakshi A, Sormani MP, Rocca MA, Bakshi R, Filippi M (2010) Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: application in multiple sclerosis. NeuroImage 50:446–455
Rocca M, Horsfield M, Sala S, Copetti M, Valsasina P, Mesaros S, Martinelli V, Caputo D, Stosic-Opincal T, Drulovic J, Comi G, Filippi M (2011) A multicenter assessment of cervical cord atrophy among MS clinical phenotypes. Neurology 76:2096–2102
Valsasina P, Rocca MA, Horsfield MA, Absinta M, Messina R, Caputo D, Comi G, Filippi M (2013) Regional cervical cord atrophy and disability in multiple sclerosis: a voxel-based analysis. Radiology 266:853–861
Miller DH, Barkhof F, Frank JA, Parker GJM, Thompson AJ (2002) Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 125:1676–1695
Bermel RA, Bakshi R (2006) The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 5:158–170
DeStefano N, Giorgio A, Battaglini M, Rovaris M, Sormani M, Barkhof F, Korteweg T, Enzinger C, Fazekas F, Calabrese M, Dinacci D, Tedeschi G, Gass A, Montalban X, Rovira A, Thompson A, Comi G, Miller D, Filippi M (2010) Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 74:1868–1876
Durand-Dubief F, Belaroussi B, Armspach JP, Dufour M, Roggerone S, Vukusic S, Hannoun S, Sappey-Marinier D, Confavreux C, Cotton F (2012) Reliability of longitudinal brain volume loss measurements between 2 sites in patients with multiple sclerosis: comparison of 7 quantification techniques. Am J Neuroradiol 33:1918–1924
Khan O, Bao F, Shah M, Caon C, Tselis A, Bailey R, Silverman B, Zak I (2012) Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study. J Neurol Sci 312:7–12
Portaccio E, Stromillo ML, Goretti B, Hakiki B, Giorgio A, Rossi F, De Leucio A, De Stefano N, Amato MP (2013) Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis: a prospective, non-randomized pilot study. Eur J Neurol 20:986–990
Radue EW, O’Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, Mueller-Lenke N, Agoropoulou C, Holdbrook F, de Vera A, Zhang-Auberson L, Francis G, Burtin P, Kappos L (2012) Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol 69:1259–1269
Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M (2012) Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 366:1000–1009
Lansley J, Mataix-Cols D, Grau M, Radua J, Sastre-Garriga J (2013) Localized grey matter atrophy in multiple sclerosis: a meta-analysis of voxel-based morphometry studies and associations with functional disability. Neurosci Biobehav Rev 37:819–830
Audoin B, Zaaraoui W, Reuter F, Rico A, Malikova I, Confort-Gouny S, Cozzone PJ, Pelletier J, Ranjeva JP (2010) Atrophy mainly affects the limbic system and the deep grey matter at the first stage of multiple sclerosis. J Neurol Neurosurg Psychiatry 81:690–695
Fisher E, Lee JC, Nakamura K, Rudick RA (2008) Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 64:255–265
Nakamura K, Fisher E (2009) Segmentation of brain magnetic resonance images for measurement of gray matter atrophy in multiple sclerosis patients. NeuroImage 44:769–776
Vrenken H, Jenkinson M, Horsfield MA, Battaglini M, van Schijndel RA, Rostrup E, Geurts JJ, Fisher E, Zijdenbos A, Ashburner J, Miller DH, Filippi M, Fazekas F, Rovaris M, Rovira A, Barkhof F, De Stefano N (2012) Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. J Neurol 260:2458–2471
Ceccarelli A, Jackson JS, Tauhid S, Arora A, Gorky J, Dell’Oglio E, Bakshi A, Chitnis T, Khoury SJ, Weiner HL, Guttmann CR, Bakshi R, Neema M (2012) The impact of lesion in-painting and registration methods on voxel-based morphometry in detecting regional cerebral gray matter atrophy in multiple sclerosis. Am J Neuroradiol 33:1579–1585
Riccitelli G, Rocca MA, Forn C, Colombo B, Comi G, Filippi M (2011) Voxelwise assessment of the regional distribution of damage in the brains of patients with multiple sclerosis and fatigue. Am J Neuroradiol 32:874–879
Benedict RH, Hulst HE, Bergsland N, Schoonheim MM, Dwyer MG, Weinstock-Guttman B, Geurts JJ, Zivadinov R (2013) Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis patients. Mult Scler 19:1478–1484
Bendfeldt K, Egger H, Nichols TE, Loetscher P, Denier N, Kuster P, Traud S, Mueller-Lenke N, Naegelin Y, Gass A, Kappos L, Radue EW, Borgwardt SJ (2010) Effect of immunomodulatory medication on regional gray matter loss in relapsing-remitting multiple sclerosis––a longitudinal MRI study. Brain Res 1325:174–182
Filippi M, Rocca MA, Pagani E, De Stefano N, Jeffery D, Kappos L, Montalban X, Boyko AN, Comi G (2013) Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg. doi:10.1136/jnnp-2013-306132
Geurts JJ, Pouwels PJ, Uitdehaag BM, Polman CH, Barkhof F, Castelijns JA (2005) Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology 236:254–260
Filippi M, Rocca MA, Benedict RH, DeLuca J, Geurts JJ, Rombouts SA, Ron M, Comi G (2010) The contribution of MRI in assessing cognitive impairment in multiple sclerosis. Neurology 75:2121–2128
Rinaldi F, Calabrese M, Seppi D, Puthenparampil M, Perini P, Gallo P (2012) Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis. Mult Scler 18:1760–1767
Nelson F, Poonawalla AH, Hou P, Huang F, Wolinsky JS, Narayana PA (2007) Improved identification of intracortical lesions in multiple sclerosis with phase-sensitive inversion recovery in combination with fast double inversion recovery MR imaging. Am J Neuroradiol 28:1645–1649
Nelson F, Poonawalla A, Hou P, Wolinsky J, Narayana P (2008) 3D MPRAGE improves classification of cortical lesions in multiple sclerosis. Mult Scler 14:1214–1219
Tallantyre EC, Morgan PS, Dixon JE, Al Radaideh A, Brookes MJ, Morris PG, Evangelou N (2010) 3 Tesla and 7 Tesla MRI of multiple sclerosis cortical lesions. J Magn Reson Imaging 32:971–977
Filippi M, Evangelou N, Kangarlu A, Inglese M, Mainero C, Horsfield MA, Rocca MA (2014) Ultra-high-field MR imaging in multiple sclerosis. J Neurol Neurosurg Psychiatry 85(1):60–66
Filippi M, Preziosa P, Pagani E, Copetti M, Mesaros S, Colombo B, Horsfield MA, Falini A, Comi G, Lassmann H, Rocca MA (2013) Microstructural magnetic resonance imaging of cortical lesions in multiple sclerosis. Mult Scler 19:418–426
Filippi M, Riccitelli G, Mattioli F, Capra R, Stampatori C, Pagani E, Valsasina P, Copetti M, Falini A, Comi G, Rocca MA (2012) Multiple sclerosis: effects of cognitive rehabilitation on structural and functional MR imaging measures––an explorative study. Radiology 262:932–940
Leavitt VM, Wylie GR, Girgis PA, DeLuca J, Chiaravalloti ND (2012) Increased functional connectivity within memory networks following memory rehabilitation in multiple sclerosis. Brain Imaging Behav. doi:10.1007/s11682-012-9183-2
Sastre-Garriga J, Alonso J, Renom M, Arevalo MJ, Gonzalez I, Galan I, Montalban X, Rovira A (2011) A functional magnetic resonance proof of concept pilot trial of cognitive rehabilitation in multiple sclerosis. Mult Scler 17:457–467
Sethi V, Yousry TA, Muhlert N, Ron M, Golay X, Wheeler-Kingshott C, Miller DH, Chard DT (2012) Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI. J Neurol Neurosurg Psychiatry 83:877–882
Acknowledgments
The author would like to thank Lisa Grauer, MSc, from Chameleon Communications International, who provided editorial support with funding from Teva Pharmaceuticals Industries Ltd., Petach Tikva, Israel.
Conflicts of interest
Massimo Filippi serves on scientific advisory boards for Teva Pharmaceutical Industries Ltd.; has received funding for travel from Bayer Schering Pharma, Biogen Idec, Merck Serono, and Teva Pharmaceutical Industries Ltd.; serves as a consultant to Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, Pepgen Corporation, and Teva Pharmaceutical Industries Ltd.; serves on speakers’ bureaus for Bayer Schering Pharma, Biogen Idec, Merck Serono, and Teva Pharmaceutical Industries Ltd.; and receives research support from Bayer Schering Pharma, Biogen Idec, Novartis, Merck Serono, Teva Pharmaceutical Industries Ltd., Fondazione Italiana Sclerosi Multipla, the Italian Ministry of Health, CurePSP, and the Gossweiler Foundation (Switzerland).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Filippi, M. MRI measures of neurodegeneration in multiple sclerosis: implications for disability, disease monitoring, and treatment. J Neurol 262, 1–6 (2015). https://doi.org/10.1007/s00415-014-7340-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-014-7340-9